PDF(Pubmed)
Abstract：
UNASSIGNED: Incorporation of luvangetin in nanoemulsions for antimicrobial and therapeutic use in infected wound healing.
UNASSIGNED: Luvangetin nanoemulsions were prepared by high-speed shear method and characterized based on their appearance structure, average droplet size, polydispersity index (PDI), electric potential, storage stability. Optimized formulation of luvangetin nanoemulsion by Box-Behnken design (BBD). The antimicrobial activity and antimicrobial mechanism of luvangetin nanoemulsions against common hospital pathogens, ie, Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), were investigated using luvangetin nanoemulsions. The biosafety of luvangetin nanoemulsion was evaluated through cytotoxicity, apoptosis, and reactive oxygen species (ROS) assay experiments using human normal epidermal cells and endothelial cells. Finally, the effect of luvangetin nanoemulsion on healing of infected wounds was investigated in B6 mice.
UNASSIGNED: Luvangetin nanoemulsion formulation consists of 2.5% sunflower seed oil, 10% emulsifier Span-20 and 7 minutes of shear time, and with good stability. Luvangetin nanoemulsion produces antibacterial activity against S. aureus and E. coli by disrupting the structure of bacterial cell membranes. Luvangetin nanoemulsion are biologically safe for HaCat and HUVEC. Luvangetin nanoemulsion showed good therapeutic effect on MRSA infected wounds in mice.
UNASSIGNED: For the first time, developed a new formulation called luvangetin nanoemulsion, which exhibited superior antibacterial effects against Gram-positive bacteria. Luvangetin nanoemulsion has a favorable effect in promoting infected wound healing. We have combined luvangetin, which has multiple activities, with nanoemulsions to provide a new topical fungicidal formulation, and have comprehensively evaluated its effectiveness and safety, opening up new possibilities for further applications of luvangetin.
UNASSIGNED: Luvangetin nanoemulsions were prepared by high-speed shear method and characterized based on their appearance structure, average droplet size, polydispersity index (PDI), electric potential, storage stability. Optimized formulation of luvangetin nanoemulsion by Box-Behnken design (BBD). The antimicrobial activity and antimicrobial mechanism of luvangetin nanoemulsions against common hospital pathogens, ie, Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), were investigated using luvangetin nanoemulsions. The biosafety of luvangetin nanoemulsion was evaluated through cytotoxicity, apoptosis, and reactive oxygen species (ROS) assay experiments using human normal epidermal cells and endothelial cells. Finally, the effect of luvangetin nanoemulsion on healing of infected wounds was investigated in B6 mice.
UNASSIGNED: Luvangetin nanoemulsion formulation consists of 2.5% sunflower seed oil, 10% emulsifier Span-20 and 7 minutes of shear time, and with good stability. Luvangetin nanoemulsion produces antibacterial activity against S. aureus and E. coli by disrupting the structure of bacterial cell membranes. Luvangetin nanoemulsion are biologically safe for HaCat and HUVEC. Luvangetin nanoemulsion showed good therapeutic effect on MRSA infected wounds in mice.
UNASSIGNED: For the first time, developed a new formulation called luvangetin nanoemulsion, which exhibited superior antibacterial effects against Gram-positive bacteria. Luvangetin nanoemulsion has a favorable effect in promoting infected wound healing. We have combined luvangetin, which has multiple activities, with nanoemulsions to provide a new topical fungicidal formulation, and have comprehensively evaluated its effectiveness and safety, opening up new possibilities for further applications of luvangetin.
摘要：
■在感染伤口愈合中用于抗微生物和治疗用途的纳米乳剂中掺入菊花苷。
■通过高速剪切法制备了Luvangetin纳米乳液，并根据其外观结构对其进行了表征，平均液滴尺寸，多分散指数(PDI)，电势,储存稳定性。通过Box-Behnken设计(BBD)优化菊苣素纳米乳的配方。樟脑苷纳米乳对常见医院病原菌的抗菌活性及抗菌机制,ie,金黄色葡萄球菌（S。金黄色葡萄球菌)和大肠杆菌(E.大肠杆菌)，使用樟脑苷纳米乳液进行了研究。通过细胞毒性评价樟脑苷纳米乳的生物安全性,凋亡，和使用人正常表皮细胞和内皮细胞的活性氧（ROS）测定实验。最后,在B6小鼠中研究了姜黄素纳米乳对感染伤口愈合的影响。
■Luvangetin纳米乳液配方由2.5％葵花籽油组成，10%乳化剂Span-20和7分钟的剪切时间，并具有良好的稳定性。Luvangetin纳米乳液通过破坏细菌细胞膜的结构产生针对金黄色葡萄球菌和大肠杆菌的抗菌活性。Luvangetin纳米乳液对HaCat和HUVEC具有生物学安全性。樟脑苷纳米乳对MRSA感染小鼠创面有较好的治疗作用。
■第一次，开发了一种名为Luvangetin纳米乳液的新配方，对革兰氏阳性细菌表现出优异的抗菌作用。Luvangetin纳米乳剂在促进感染伤口愈合方面具有良好的效果。我们结合了Luvangetin，有多个活动，与纳米乳液提供一种新的局部杀真菌制剂，并全面评估了其有效性和安全性，为luvangetin的进一步应用开辟了新的可能性。
■通过高速剪切法制备了Luvangetin纳米乳液，并根据其外观结构对其进行了表征，平均液滴尺寸，多分散指数(PDI)，电势,储存稳定性。通过Box-Behnken设计(BBD)优化菊苣素纳米乳的配方。樟脑苷纳米乳对常见医院病原菌的抗菌活性及抗菌机制,ie,金黄色葡萄球菌（S。金黄色葡萄球菌)和大肠杆菌(E.大肠杆菌)，使用樟脑苷纳米乳液进行了研究。通过细胞毒性评价樟脑苷纳米乳的生物安全性,凋亡，和使用人正常表皮细胞和内皮细胞的活性氧（ROS）测定实验。最后,在B6小鼠中研究了姜黄素纳米乳对感染伤口愈合的影响。
■Luvangetin纳米乳液配方由2.5％葵花籽油组成，10%乳化剂Span-20和7分钟的剪切时间，并具有良好的稳定性。Luvangetin纳米乳液通过破坏细菌细胞膜的结构产生针对金黄色葡萄球菌和大肠杆菌的抗菌活性。Luvangetin纳米乳液对HaCat和HUVEC具有生物学安全性。樟脑苷纳米乳对MRSA感染小鼠创面有较好的治疗作用。
■第一次，开发了一种名为Luvangetin纳米乳液的新配方，对革兰氏阳性细菌表现出优异的抗菌作用。Luvangetin纳米乳剂在促进感染伤口愈合方面具有良好的效果。我们结合了Luvangetin，有多个活动，与纳米乳液提供一种新的局部杀真菌制剂，并全面评估了其有效性和安全性，为luvangetin的进一步应用开辟了新的可能性。
